PASSING A US FDA GMP INSPECTION: A-Z Guaranteeing a Pass the First Time through an FDA Inspection

Instructor: Michael Anisfeld
Product ID: 701026
  • Duration: 90 Min

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556


Read Frequently Asked Questions

In this FDA cGMP Inspection training learn all the background information and key Techniques needed to guarantee a cost-effective, first-time pass through an FDA inspection - whether for a pharmaceutical product, an active pharmaceutical ingredient (API), a medical Device or a biological production.


The world of GMP compliance has dramatically changed with FDA stressing pre-approval inspections, risk management, investigations and CAPA, quality systems approaches, and process and analytical technology (PAT) applications. If you last passed an FDA inspection more than four years ago, or if you have never faced an FDA inspection, you will be unprepared for FDA’s 21st-century inspection methods. This course provides all the background information and key techniques needed to guarantee a cost-effective, first-time pass through an FDA inspection— whether for a pharmaceutical product, an active pharmaceutical ingredient (API), a medical device or a biological product. All API, medical device, diagnostic product manufacturer, biotechnology product or pharmaceutical manufacturers—no matter in which country they operate—must pass an on-site FDA inspection of their facilities and operations if products are to be sold in the United States.

This webinar is designed to provide background and insight into the inspection process, as well as practical strategies and tactics that a company must know and implement in order to have the potential to pass an inspection the first time through. The webinar covers everything you need to know—from the background to the inspection, including the importance of the commitments made in the product application (the DMF, the NDA, the BLA or the PMA). In addition we will discuss the differences between good science and GMP compliance issues. The inspection process itself will be analyzed and reviewed in a manner that will allow you to immediately begin effective strategizing on how to pass the inspection. Nothing has been left out. The course touches on everything, and we do mean everything, you need to know to have a smooth and successful inspection.

Areas Covered in the Webinar:

  • FDA inspection objectives.
  • FDA’s 21st-century initiatives and their impact on inspections:
    • Quality systems approaches and inspections
    • Risk management
    • Changes to FDA’s ONDC review process
    • Process and analytical technology (PAT)
    • Electronic records/electronic signatures (21CFR11)
  • The approval process and how inspections are planned and triggered
  • The differences between a GMP and a pre-approval inspection (PAI)
  • Strategies of companies that have been successful; Lessons from companies that have failed
  • Paying for an inspection
  • Preparing for an inspection: key elements that must be covered
  • Training your company staff
  • How to handle an inspector
  • Key do’s and don’ts: things that will kill you during an inspection
  • What the inspector is looking for in:
    • Batch documentation
    • Stability studies
    • Validation documentation
  • FDA’s inspection techniques: system inspections explained
  • FDA strategies for PAI inspections
  • FDA’s expectations from:
    • Your CAPA systems (Corrective Actions and Preventive Actions)
    • Your environmental trending reports
  • What documents you need to show the FDA
  • Effective investigation of:
    • Complaints
    • Out-of-specifications, out-of-trends
  • Environmental monitoring requirements
  • What to say (and what not to say) to an inspector
  • The five validation inspections: what FDA looks for in validations
  • Bribery, corruption, fraud: how to entertain FDA legitimately
  • Documentation requirements: before, during and after the inspection
  • Follow-up by FDA after an inspection
  • FDA application integrity policy and import alert system
  • Follow-up by the company after an inspection
    • What to say, and how to say it
    • Rescuing yourself from a marginal inspection

At the end of the course you will:

  • Understand the mechanics and extent of an FDA inspection.
  • Be fully aware of FDA’s risk management and quality systems approaches to GMP compliance.
  • Realize how FDA’s 21st century GMP initiatives have changed the inspection landscape.
  • Know how to prepare yourself and your company for an inspection.
  • Recognize the traps and pitfalls facing you in an inspection.
  • Know why you pass or fail an inspection in the first fifteen minutes.
  • Understand why you absolutely cannot afford to fail an FDA inspection

Who will benefit:

  • Senior management who will deal with FDA inspectors
  • Regulatory affairs professionals and quality assurance personnel
  • Production
  • Engineering
  • Validation
  • Quality control and research and development staff who will be facing an FDA inspector will find this seminar essential preparation and key to the company’s success at the inspection.

Instructor Profile:

Michael Anisfeld, is senior consultant for Globepharm Consulting specializing in GMP/Quality activities for the healthcare manufacturing industries. In his current position he numbers among his clients United Nations Agencies, national regulatory agencies (including the US-FDA) and more than 200 pharmaceutical, medical device, biotechnology and bulk pharmaceutical companies in North America, Europe and Asia. Mr. Anisfeld has established and directed quality control, quality assurance, production and materials management functions in the industry. He has instituted innovative, cost-effective auditing Programmes for his clients, ensuring that they pass regulatory inspections the first time. With over twenty-five years expertise in the healthcare industry, Mr. Anisfeld has held senior management positions in international technology transfer, quality assurance, quality control and production.

In the course of his career, he has designed pharmaceutical, medical device and bulk pharmaceutical chemical facilities in seven countries. A member of the faculty of the University of Illinois, where he lectures in pharmaceutical technology, Mr. Anisfeld holds higher degrees in Pharmaceutical Technology (M.Sc.), Management (MSM) and Business Administration (MBA). An active member of many European and American regulatory and technical associations, he has served on the Board of Directors of the Parenteral Drug Association (PDA) and been chairman of its quality control and aseptic processing task groups. He currently serves on the FIP Task Force on Counterfeit Drugs and other international industry forums. An acclaimed international lecturer on the subject of GMP and quality topics, Mr. Anisfeld is also a prolific author on these subjects. He is the editor and author of many texts, including: International Drug GMPs, International Device GMPs, and Guide to FDA Pre-Approval Inspections, Sterile Pharmaceutical Manufacturing, and PDA’s monograph Validation of Aseptic Processing of Liquid Drug Products.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
21 CFR Part 11 Compliance for SaaS/Cloud Applications - 80202SEM

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed